S(+) versus racemic ibuprofen

Klein, Gunnar; Neff, H.; Kullich, W.; Phleps, W.; Kollenz, C J

doi:10.1016/0140-6736(92)90842-q

Cited by 12 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present clinical trial confirm at least noninferiority of both dexibuprofen doses compared to conventional ibuprofen at a common dose for the investigated indication. These results are supported by other clinical trials demonstrating noninferiority of dexibuprofen compared to the double dose of conventional ibuprofen in different indications [14,[16][17][18] . The descriptive analyses of the additionally assessed pain criteria support the results of the confirmatory analyses.…”

Section: Discussionsupporting

confidence: 77%

“…The presence of R -ibuprofen decreased the potency of S -ibuprofen much more than theoretically expected [25] . Bridging studies versus conventional ibuprofen and studies versus other NSAIDs including celecoxib confirm the good relative efficacy and tolerability profile of dexibuprofen [14,[16][17][18] . Results from clinical trials demonstrate that at a dose ratio of 0.5: 1 dexibuprofen is at least equally effective and safe as conventional ibuprofen [14,[16][17][18] .…”

Section: Discussionmentioning

confidence: 99%

“…In clinical trials and in postmarketing surveillance studies, more than 12,000 patients were treated with dexibuprofen in a special crystal form. The results of these trials show that a dose ratio of 0.5: 1 of dexibuprofen versus conventional ibuprofen provided adequate analgesia [14,[16][17][18] .…”

mentioning

confidence: 99%

See 2 more Smart Citations

ADIDAC Trial: Analgesia with Dexibuprofen versus Ibuprofen in Patients Suffering from Primary Dysmenorrhea: A Crossover Trial

Kollenz

Phleps

Kaehler³

2008

Gynecol Obstet Invest

Self Cite

View full text Add to dashboard Cite

Background: Primary dysmenorrhea is estimated to affect 40–50% of menstruating young women. Methods: Randomized, double-blind, 3-cycle crossover, active-controlled clinical trial conducted in 102 outpatients. Results: 102 patients entered the study and 77 were eligible for analyses. The mean (SD) age was 31.1 (7.0) years, and the mean cycle duration was 28.1 days (1.89) with a mean menstrual phase of 5.3 days (1.28). 40.26% of patients reported moderate pain from dysmenorrhea, and the remaining 59.74% reported severe pain. Compared to ibuprofen 400 mg, both dexibuprofen doses (200 and 300 mg) showed a trend towards superiority for sum of pain intensity difference (sum of PID), PID and total pain relief. Furthermore, dexibuprofen 200 mg had a faster onset of action compared to the double dose of ibuprofen (p = 0.035). A dose-effect relationship could be demonstrated for dexibuprofen in this visceral pain model. Tolerability was similar across all treatments. Conclusions: In patients experiencing acute visceral pain as a result of primary dysmenorrhea, dexibuprofen was associated with a dose-dependent effective analgesia; this effect was at least equivalent to that of the double dose of ibuprofen. With its lower body-loading dose, dexibuprofen expands the alternatives available to treat this condition.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ADIDAC Trial: Analgesia with Dexibuprofen versus Ibuprofen in Patients Suffering from Primary Dysmenorrhea: A Crossover Trial

Kollenz

Phleps

Kaehler³

2008

Gynecol Obstet Invest

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some studies have compared dexibuprofen and racemic ibuprofen in diseases other than fever. In randomized uncontrolled studies that compared with ibuprofen or diclofenac, usual daily doses of dexibuprofen, 900 to 1200 mg, was efficacious for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and other rheumatic diseases [30–32]. The efficacy of dexibuprofen and ibuprofen was comparable when dexibuprofen was administered at a 50% lower dose [20, 31, 32].…”

Section: Discussionmentioning

confidence: 99%

“…In randomized uncontrolled studies that compared with ibuprofen or diclofenac, usual daily doses of dexibuprofen, 900 to 1200 mg, was efficacious for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and other rheumatic diseases [30–32]. The efficacy of dexibuprofen and ibuprofen was comparable when dexibuprofen was administered at a 50% lower dose [20, 31, 32]. However, the period of these studies was short and not placebo controlled, meaning most of them suffered from deficiencies in design and implementation, and dexibuprofen has not been compared with placebo.…”

Section: Discussionmentioning

confidence: 99%

The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection

Yoon

Jeong

et al. 2008

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The analgesic and anti-inflammatory efficacy of dexibuprofen compared with ibuprofen in adults with osteoarthritis, rheumatoid arthritis and dental pain. WHAT THIS STUDY ADDS• Dexibuprofen is as effective and tolerable as ibuprofen, and a dose of 5 mg kg -1 of dexibuprofen would be sufficient to control fever caused by upper respiratory tract infection in children. AIMTo evaluate the antipyretic efficacy and tolerability of dexibuprofen compared with ibuprofen in children with fever caused by upper respiratory tract infection (URTI). METHODSThe study population consisted of children aged 6 months to 14 years. At the time of visit to the hospital, the children had fever; the cause of fever was determined to be URTI by a paediatrician based on history taking and physical examination. The study was a multicentre, randomized, double-blind, controlled parallel group, comparative, Phase 3 clinical trial, conducted at three hospitals. By using a computer-based random assignment program, the subjects were allocated to the following three groups: 5 mg kg -1 dexibuprofen group, 7 mg kg -1 dexibuprofen group, and 10 mg kg -1 ibuprofen group. RESULTSIn the clinical trial of the antipyretic action of dexibuprofen in patients with fever caused by URTI, there was no statistically significant difference in maximal decrease of temperature and mean time to become apyrexial among the 5 mg kg -1 dexibuprofen, 7 mg kg -1 dexibuprofen and 10 mg kg -1 ibuprofen groups (P > 0.05). There also was no significant difference in adverse drug reaction (P > 0.05). CONCLUSIONSDexibuprofen is as effective and tolerable as ibuprofen. A dose of 5 mg kg -1 and 7 mg kg -1 dexibuprofen in place of 10 mg kg -1 ibuprofen would be sufficient to control fever caused by URTI in children.

show abstract